Follow The Filings

BBWI Bath & Body Works Inc.

Consumer Discretionary, filed as BATH & BODY WORKS INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • $159K
  • 1 new

In 2026 Q3 Greenhaven Associates opened a position in Bath & Body Works.

Who owns BBWI

Sorted by value, long equity only, as of 2026 Q3.

History
Greenhaven Associates <0.01% New <0.01% 10,000 $159K History

1 current, options excluded

Insider trades

Open-market buys and sales by BBWI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BBWI insider trades
  • $1M bought by 6 insiders
  • $14 sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Sarah E Nash Director
    Sale
    $14 1 share at $20.56 <0.1% of stake
    Traded Oct 16 Filed Oct 20
    ↗
  2. James Kevin Symancyk Director
    Buy
    $351K 22,500 shares at $15.58 +126% to stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗
  3. Sarah E Nash Director
    Buy
    $156K 10,000 shares at $15.58 +3.6% to stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗
  4. Steven E Voskuil Director
    Buy
    $301K 20,000 shares at $15.04 +144% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗
  5. Stephen D Steinour Director
    Buy
    $100K 6,700 shares at $14.86 +16% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗
  6. Francis Hondal Director
    Buy
    $50K 3,343 shares at $15.00 +18% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗
  7. Lucy Brady Director
    Buy
    $50K 3,470 shares at $14.40 +25% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 15 stock grants and 4 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,5.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K ANNUAL REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $7.56B $7.43B $7.31B
Gross profit $3.26B $3.24B $3.23B
Gross margin * 43.1% 43.6% 44.3%
Net income $800M $878M $798M
Net margin * 10.6% 11.8% 10.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.27B $2.12B $1.82B
Total non-current assets * $3.23B $3.35B $3.05B
Total assets $5.49B $5.46B $4.87B
Total current liabilities $1.38B $1.29B $1.23B
Total equity -$2.21B -$1.63B -$1.38B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.14B $0.954B $0.886B
Cash from investing -$328M -$286M -$162M
Cash from financing -$1.56B -$0.815B -$1.13B
Net change in cash -$747M -$148M -$410M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.